Protective effects of silymarin on cardiac and hepatic side effects of chemotherapy drugs
Not Applicable
- Conditions
- Acute lymphoblastic leukemia.Acute lymphoblastic leukaemia [ALL]
- Registration Number
- IRCT2017071935175N1
- Lead Sponsor
- Vice chancellor for research, Isfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Diagnosis of ALL based on bone marrow morphology and immunophenotype; Age 2-14 years; Therapy in maintenance phase of childhood ALL (at least 6 months);
Exclusion criteria: Previous history of liver and heart disease; Take any other medicines except chemotherapy drug
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver enzymes: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP). Timepoint: Before, 3 and 6 months after intervention. Method of measurement: Blood test.;Cardiac function. Timepoint: Before, 3 and 6 months after intervention. Method of measurement: Echocardiography, measuring enzyme Creatine kinase- Muscle and Brain (CK-MB) and Lactate Dehydrogenase (LDH).;Coagulation testes: Prothrombin Time (PT), activeted Partial Tromboplastin Time (aPTT) and International Normal Ratio (INR). Timepoint: Before, 3 and 6 months after intervention. Method of measurement: Blood test.
- Secondary Outcome Measures
Name Time Method Ejection Fraction (EF). Timepoint: Before, 3 and 6 months after intervention. Method of measurement: Ecocardiography.;Cardiac Systolic Function (SF). Timepoint: Before, 3 and 6 months after intervention. Method of measurement: Ecocardiography.